UnknownNot Applicable

Oral Contraceptive Pills Versus Expectant Management for Retained Pregnancy Products

100 participantsStarted 2017-09

Plain-language summary

We speculate that the use of combined oral contraceptives may be a possible solution to promote the management of retained pregnancy products versus expectant management. By withdrawing the pill, the endometrium is expected to shed in a synchronized fashion (estrogen and progestin withdrawal bleeding and may also shed the retained products of conception and avoid a surgical procedure with its related potential complications.

Who can participate

Age range16 Years – 54 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients going through a Misoprostol or Misoprostol/Mifepristone induced procedure after a spontaneous 1st trimester pregnancy loss or as a 1st trimester planned pregnancy termination and present retained pregnancy products by a trans-vaginal ultrasound scan.
✓. Patients after a surgical evacuation of pregnancy products (dilatation and curettage - D\&C) of a 1st trimester miscarriage and present retained pregnancy products by a trans-vaginal ultrasound scan.
✓. All retained products included are of a previously confirmed intra-uterine pregnancies.
✓. Asymptomatic patients or mild symptoms of bleeding (spotting).
✓. Presence of a measurable hyperechoic material by 2 dimensional TVUS

Exclusion criteria

✕. Retained products with any of the following clinical presentations : more than a mild vaginal bleeding, hemodynamic instability, signs of infection and/or abdominal pain.
✕. Any suspicion of a molar pregnancy.
✕. A known contra-indication for the use of oral contraceptives

What they're measuring

persistent retained pregnancy products rate

Timeframe: 4 weeks

Trial details

NCT IDNCT03230825

SponsorMeir Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-09

Contact for this trial

Anat Hershko Klement, MD

+972549170084 anat.klement@gmail.com

View on ClinicalTrials.gov More Retained Products of Conception Post Abortion trials